<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ALFENTANIL HYDROCHLORIDE</span><br/>(al-fen'ta-nill)<br/><span class="topboxtradename">Alfenta<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">narcotic (opiate) agonist analgesic</span>; <span class="classification">general anesthetic</span><br/><b>Prototype: </b>Morphine<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule II<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Alfentanil is a narcotic agonist analgesic with rapid onset and short duration of action. CNS effects of alfentanil appear
         to be related to interaction of drug with opiate receptors.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Brief duration is advantageous for short surgical procedures but necessitates incremental injections or continuous infusion
         for long operations.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Major component of balanced anesthesia; analgesic, analgesic supplement, and primary anesthetic for induction of anesthesia
         when endotracheal and mechanical ventilation are required.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Safety during pregnancy (category C), lactation, or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Older adults, history of pulmonary disease.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Anesthesia Induction</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 820 mcg/kg for surgery lasting </td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> Direct or Continuous:</span>  Alfentanil is available in concentrations of 500 mcg/mL. Add 20 mL of alfentanil to 230 mL of compatible IV solution to yield 40 mcg/mL. Compatible IV solutions include NS, D5/NS,
                  D5W, and RL. 
                  								Note: Alfentanil may be diluted to concentrations of 2580 mcg/mL.
                  							 
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span>  Administer over at least 3 min. Do not administer more rapidly.  <span class="methodtype"> Continuous:</span> Administer at a rate of 0.51 mcg/kg/min. Note: Dose may be individualized.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Amphotericin B, thiopental.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30° C (59°86° F). Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Thoracic muscle rigidity, flushing, diaphoresis; extremities feel heavy and warm. <span class="typehead">CNS:</span> Dizziness, euphoria, drowsiness. <span class="typehead">CV:</span> Hypotension, hypertension, tachycardia, bradycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea,</span> vomiting, anorexia, constipation, cramps. <span class="typehead">Respiratory:</span> Apnea, respiratory depression, dyspnea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">beta-adrenergic blockers</span> increase incidence of bradycardia; <span class="classification">cns depressants</span> such as <span class="classification">barbiturates</span>, <span class="classification">tranquilizers</span>, <span class="classification">neuromuscular blocking agents</span>, <span class="classification">opiates</span>, and <span class="classification">inhalation general anesthetics</span> may enhance the cardiovascular and CNS effects of alfentanil in both magnitude and duration; enhancement or prolongation
      of postoperative respiratory depression also may result from concomitant administration of any of these agents with alfentanil. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 2 min. <span class="typehead">Duration:</span> Injection 30 min; continuous infusion 45 min. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Completely metabolized in liver. <span class="typehead">Elimination:</span> Excreted in breast milk. <span class="typehead">Half-Life:</span> 46213 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of increased sympathetic stimulation (arrhythmias) and evidence of depressed postoperative analgesia (tachycardia,
            pain, pupillary dilation, spontaneous muscle movement) if a narcotic antagonist has been administered to overcome residual
            effects of alfentanil.
         </li>
<li>Evaluate adequacy of spontaneous ventilation carefully during postoperative period.</li>
<li>Monitor vital signs carefully during postoperative period; check for bradycardia, especially if patient is also taking a beta
            blocker.
         </li>
<li>
            							Note: Narcotic effects wear off quickly with negligible residual effects.
            						
         </li>
<li>
            							Note: Dizziness, sedation, nausea, and vomiting are common when drug is used as a postoperative analgesic.
            						
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unpleasant adverse effects when drug is used for patient-controlled analgesia.</li>
<li>Do not breast feed infants while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>